232 related articles for article (PubMed ID: 15887068)
1. Biostatistical methods for demonstrating efficacy in the regulatory setting. An epistemological approach to adaptive designs.
Koch A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):572-9. PubMed ID: 15887068
[TBL] [Abstract][Full Text] [Related]
2. Confirmatory clinical trials with an adaptive design.
Koch A
Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
[TBL] [Abstract][Full Text] [Related]
3. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
Atkinson AC; Biswas A
Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
[TBL] [Abstract][Full Text] [Related]
4. Adaptive design of confirmatory trials: Advances and challenges.
Lai TL; Lavori PW; Tsang KW
Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
[TBL] [Abstract][Full Text] [Related]
5. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
6. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
7. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
8. A 25-year review of sequential methodology in clinical studies.
Todd S
Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
[TBL] [Abstract][Full Text] [Related]
9. Adaptive clinical trials for new drug applications in Japan.
Ando Y; Hirakawa A; Uyama Y
Eur Neuropsychopharmacol; 2011 Feb; 21(2):175-9. PubMed ID: 20961739
[TBL] [Abstract][Full Text] [Related]
10. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
11. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
Martin PJ; Weisdorf D; Przepiorka D; Hirschfeld S; Farrell A; Rizzo JD; Foley R; Socie G; Carter S; Couriel D; Schultz KR; Flowers ME; Filipovich AH; Saliba R; Vogelsang GB; Pavletic SZ; Lee SJ;
Biol Blood Marrow Transplant; 2006 May; 12(5):491-505. PubMed ID: 16635784
[TBL] [Abstract][Full Text] [Related]
12. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
13. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
Mauer M; Collette L; Bogaerts J;
Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
[TBL] [Abstract][Full Text] [Related]
14. A comparison of methods for adaptive treatment selection.
Friede T; Stallard N
Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Dunnett tests for treatment selection.
Koenig F; Brannath W; Bretz F; Posch M
Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
[TBL] [Abstract][Full Text] [Related]
16. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
17. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
18. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
Kelly PJ; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
[TBL] [Abstract][Full Text] [Related]
19. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
Kimani PK; Todd S; Stallard N
Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
[TBL] [Abstract][Full Text] [Related]
20. A review of phase 2-3 clinical trial designs.
Thall PF
Lifetime Data Anal; 2008 Mar; 14(1):37-53. PubMed ID: 17763973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
